hese are challenging times for governments, public health administrations and the financial markets. While each biopharma company’s primary concern is the health and safety of its team members
In the summer of 2019, Locust Walk launched a blog post, Financing overhang or hangover: The impact on partnerships for public biotech companies, that was born out of observations and conversations with many public, non-revenue generating biotech companies over the years.
Locust Walk has been active in Asia, in particular, Japan for nearly half of the firm’s history and we are deeply rooted in the market. We have advised on more than a dozen transactions during our history in Japan and have successfully helped deal making between US/EU companies and Japan pharma.
Based on recent acquisition activity by two of the largest pharmaceutical companies, it seems as if the historical orthodoxy that great biopharma companies are made from the inside out may be losing validity.
I recently returned from a month in Europe as part of our effort to expand Locust Walk’s European practice. It was an amazing trip meeting great people and learning valuable lessons.
Biotech companies are attracted to licensing deals for a variety of important reasons: 1) to provide an alternative source of capital from the licensee to fund R&D and commercial operations including,
Clear, data-based financial assumptions are essential to driving a successful deal process. In a previous post, The Value of a Commercial Assessment in Supporting a Transaction
Pursuing multiple deal options in parallel, known as a multi-track process, can create competitive tension that will enable a company to obtain the most value out of the deal
It is that time of year again when the orthopedics community comes together to reflect on the recent American Academy of Orthopedic Surgeons (AAOS) meeting which took place in Las Vegas and finished late last week.
In this whitepaper, you’ll discover China and Japan are combining to invigorate the deal making landscape in Asia, even though their biopharma ecosystem dynamics are markedly different. Regardless, they are affecting deal making strategies globally.